Inclusion Criteria:

• Subject is male and at least 18 years of age.
• Subject has histologically- or cytologically-confirmed prostate adenocarcinoma with metastatic, progressive disease while on androgen deprivation therapy.
• Subject has radiograph-documented (computed tomography, magnetic resonance imaging or x-ray) metastatic disease.
• Subject has undergone orchiectomy or is expected to continue receiving luteinizing hormone-releasing hormone analogue therapy, and has a testosterone level of <50 ng/dL at screening.
• Subject has discontinued all antiandrogen therapy (within 4 weeks for flutamide and within 6 weeks for all others) prior to their first dose of study drug.
• Subject has a prostate-specific antigen level ≥5 ng/mL.
• Subject has clinical laboratory evaluations (including clinical chemistry, hematology, and complete urinalysis) within the reference range for the testing laboratory, unless the results are deemed not clinically significant by the investigator or sponsor.
• Subject has a screening ejection fraction that is above the lower limit of the institutional normal range.
• Subject has ECOG performance status of 0 to 2.
• Subject has an absolute neutrophil count ≥1500/uL, a platelet count ≥100,000/uL and hemoglobin ≥10g/dL.
• Subject has a serum aspartate aminotransferase levels ≤ 1.5 times the institutional upper limit of normal, and bilirubin levels ≤ 1.5 times the institutional upper limit of normal;
• Subject has cardiac enzyme results (CK-MB and troponins I&T) within the reference ranges for the testing laboratory.
• Subject has normal or, in the opinion of the investigator, clinically insignificant, physical examination findings, ECG and chest x-ray results.

Exclusion Criteria:

• Subject has known hypersensitivity to TAK-700 or related compounds.
• Subject has received prior therapy with aminoglutethimide or ketoconazole within 30 days prior to the first dose of study drug.
• Subject has received prior chemotherapy for prostate cancer.
• Subject has received any investigational compound within 30 days prior to first dose of study drug.
• Subject has received prior herbal product known to decrease prostate-specific antigen levels (eg, Saw Palmetto, PC-SPES) within 30 days prior to the first dose of study drug.
• Subject has received radiation therapy for prostate cancer within 30 days prior to first dose of study drug.
• Chronic therapy with oral or other systemically administered corticosteroids, such as prednisone, within 30 days prior to Screening. Chronic therapy is defined as the use of corticosteroids for more than 7 days within a 30-day period.
• Subject has current spinal cord compression, current bilateral hydronephrosis, or current bladder neck outlet obstruction.
• Subject has a history of adrenal insufficiency.
• Subject has a history of myocardial infarction, ischaemic symptomatic heart disease, cardiac arrhythmias or thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any other cardiac condition (e.g., pericardial effusion restrictive cardiomyopathy) within 12 months prior to first dose of study drug.
• Subject has any symptoms which the investigator deems related to prostate cancer, i.e., bone pain, pelvic pain.
• Subject has a history of congestive heart failure (New York Heart Association Class II or greater.
• Subject has history of another malignancy other than basal cell carcinoma or state 1 squamous cell carcinoma of the skin, within the last 5 years.
• Subject has uncontrolled hypertension.
• Subject has a serious medical condition or psychiatric illness that might affect life expectancy or make it difficult to successfully manage and follow the subject.
• Subject is unable to understand verbal or written English or any other language for which a certified translation of the institutional review board (IRB)-approved informed consent has been provided.
• Subject is unwilling or unable to comply with the protocol or cooperate fully with the investigator and site personnel.